July 21, 2023
- July 29, 2020 - NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional). See NOFO PAR-20-285.
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this notice is to inform applicants of an extension to PAR-20-285 "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)" by one additional council round. Due to the extension, the following application due dates have been added/changed:
New Application Due Date: October 18, 2023
Resubmission/Revision Due Date(s): November 17, 2023
Expiration Date: November 18, 2023
Changes to the Key Dates are shown below.
Currently Reads:
Part 1. Overview Information
Key Dates
| Application Due Date(s) | New Applications: October 14, 2020; February 18, 2021; June 18, 2021; October 14, 2021; February 22, 2022; June 20, 2022; October 18, 2022; February 14, 2023, June 14, 2023 by 5:00 PM local time of applicant organization. Resubmission or Revision Applications: November 18, 2020; March 22, 2021; July 14, 2021; November 18, 2021, March 22, 2022; July 20, 2022; November 18, 2022; March 14, 2023, July 23, 2023 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | February 2021, July 2021, October 2021, February 2022, July 2022, October 2022, February 2023, July 2023, October 2023 |
| Advisory Council Review | May 2021, October 2021, January 2022, May 2022, October 2022, January 2023, May 2023, October 2023, January 2024 |
| Earliest Start Date | June 2021, November 2021, February 2022, June 2022, November 2022, February 2023, June 2023, November 2023, February 2024 |
| Expiration Date | July 24, 2023 |
Modified to Read:
Part 1. Overview Information
Key Dates
| Application Due Date(s) | New Applications: October 14, 2020; February 18, 2021; June 18, 2021; October 14, 2021; February 22, 2022; June 20, 2022; October 18, 2022; February 14, 2023, June 14, 2023, October 18, 2023 by 5:00 PM local time of applicant organization. Resubmission or Revision Applications: November 18, 2020; March 22, 2021; July 14, 2021; November 18, 2021, March 22, 2022; July 20, 2022; November 18, 2022; March 14, 2023, July 23, 2023, November 17, 2023 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
| Scientific Merit Review | February 2021, July 2021, October 2021, February 2022, July 2022, October 2022, February 2023, July 2023, October 2023, February 2024 |
| Advisory Council Review | May 2021, October 2021, January 2022, May 2022, October 2022, January 2023, May 2023, October 2023, January 2024, May 2024 |
| Earliest Start Date | June 2021, November 2021, February 2022, June 2022, November 2022, February 2023, June 2023, November 2023, February 2024, June 2024 |
| Expiration Date | November 18, 2023 |
All other aspects of this NOFO remain unchanged.
Scott Janis, Ph.D.
National Institute of Neurological Disorders & Stroke (NINDS)
Telephone: 301-496-9135
Email: [email protected]
and Human Services (HHS)
